The stock of Regulus Therapeutics Inc (NASDAQ:RGLS) is a huge mover today! About 290,416 shares traded hands. Regulus Therapeutics Inc (NASDAQ:RGLS) has declined 52.47% since March 8, 2016 and is downtrending. It has underperformed by 61.78% the S&P500.
The move comes after 5 months negative chart setup for the $182.72 million company. It was reported on Oct, 11 by Barchart.com. We have $2.88 PT which if reached, will make NASDAQ:RGLS worth $20.10M less.
Analysts await Regulus Therapeutics Inc (NASDAQ:RGLS) to report earnings on November, 3. They expect $-0.38 earnings per share, down 52.00% or $0.13 from last year’s $-0.25 per share. After $-0.40 actual earnings per share reported by Regulus Therapeutics Inc for the previous quarter, Wall Street now forecasts -5.00% EPS growth.
Regulus Therapeutics Inc (NASDAQ:RGLS) Ratings Coverage
Out of 5 analysts covering Regulus Therapeutics (NASDAQ:RGLS), 4 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 80% are positive. Regulus Therapeutics has been the topic of 9 analyst reports since August 5, 2015 according to StockzIntelligence Inc. On Wednesday, April 13 the stock rating was initiated by Chardan Capital Markets with “Buy”. The company was initiated on Tuesday, April 12 by BMO Capital Markets. The firm has “Buy” rating by Chardan Capital Markets given on Tuesday, June 7. The stock of Regulus Therapeutics Inc (NASDAQ:RGLS) earned “Market Perform” rating by BMO Capital Markets on Tuesday, June 28. Wedbush maintained the shares of RGLS in a report on Wednesday, August 5 with “Buy” rating. The rating was initiated by Wells Fargo on Friday, December 4 with “Outperform”. Needham maintained Regulus Therapeutics Inc (NASDAQ:RGLS) rating on Tuesday, June 28. Needham has “Buy” rating and $10 price target. The firm has “Buy” rating by Chardan Capital Markets given on Tuesday, June 28.
According to Zacks Investment Research, “Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company’s products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus Therapeutics Inc. is based in La Jolla, California.”
Insitutional Activity: The institutional sentiment increased to 1.23 in Q2 2016. Its up 0.19, from 1.04 in 2016Q1. The ratio improved, as 26 funds sold all Regulus Therapeutics Inc shares owned while 14 reduced positions. 6 funds bought stakes while 43 increased positions. They now own 27.05 million shares or 18.99% less from 33.39 million shares in 2016Q1.
Citigroup Incorporated holds 0% or 14,322 shares in its portfolio. The Connecticut-based Cubist Systematic Strategies Ltd Liability Company has invested 0% in Regulus Therapeutics Inc (NASDAQ:RGLS). The Pennsylvania-based Nationwide Fund has invested 0% in Regulus Therapeutics Inc (NASDAQ:RGLS). Proshare Advsr Ltd Liability Corporation has invested 0% of its portfolio in Regulus Therapeutics Inc (NASDAQ:RGLS). Teachers Retirement Sys Of The State Of Kentucky holds 0% of its portfolio in Regulus Therapeutics Inc (NASDAQ:RGLS) for 108,900 shares. Citadel Advsr Limited Liability owns 16,897 shares or 0% of their US portfolio. State Street Corporation has 551,539 shares for 0% of their US portfolio. Comml Bank Of New York Mellon Corp accumulated 141,216 shares or 0% of the stock. Mufg Americas Hldg has 1,155 shares for 0% of their US portfolio. Zurcher Kantonalbank (Zurich Cantonalbank) holds 0% or 1,123 shares in its portfolio. Vanguard Gru Incorporated reported 1.28 million shares or 0% of all its holdings. Blackrock Limited Liability last reported 0% of its portfolio in the stock. Kcg Hldgs holds 0% or 80,941 shares in its portfolio. Moreover, California Public Employees Retirement Sys has 0% invested in Regulus Therapeutics Inc (NASDAQ:RGLS) for 208,100 shares. Goldman Sachs last reported 0% of its portfolio in the stock.
More important recent Regulus Therapeutics Inc (NASDAQ:RGLS) news were published by: Fool.com which released: “Regulus Therapeutics Inc. Clinical Hold: Should Investors Be Yellow-Bellied?” on June 28, 2016, also Fool.com published article titled: “Why Regulus Therapeutics Inc. Fell 20.1% in April”, Marketwatch.com published: “Regulus Therapeutics’ stock set to fall after FDA places hepatitis C treatment …” on June 27, 2016. More interesting news about Regulus Therapeutics Inc (NASDAQ:RGLS) was released by: 247Wallst.com and their article: “Regulus Therapeutics Soars Over Interim HCV Results” with publication date: February 17, 2016.
RGLS Company Profile
Regulus Therapeutics Inc., incorporated on September 5, 2007, is a biopharmaceutical firm focused on discovering and developing drugs that target microribonucleic acid (microRNAs) to treat a range of diseases. The Firm uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. The Company’s Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease. It has a research collaboration with Biogen focused on the discovery of microRNAs as biomarkers for multiple sclerosis and has completed research for another pharmaceutical firm to explore microRNAs as biomarkers for specific patient populations.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.